1. Home
  2. CLPS vs SABS Comparison

CLPS vs SABS Comparison

Compare CLPS & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

SELL

Current Price

$1.06

Market Cap

36.0M

Sector

Technology

ML Signal

SELL

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$4.05

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
SABS
Founded
2005
2014
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
201.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CLPS
SABS
Price
$1.06
$4.05
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.80
AVG Volume (30 Days)
14.8K
297.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
12.62%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.00
52 Week High
$1.88
$6.60

Technical Indicators

Market Signals
Indicator
CLPS
SABS
Relative Strength Index (RSI) 48.17 53.13
Support Level $0.90 $3.43
Resistance Level $1.08 $4.14
Average True Range (ATR) 0.05 0.27
MACD -0.02 0.01
Stochastic Oscillator 13.33 70.70

Price Performance

Historical Comparison
CLPS
SABS

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: